Loading...
•
Jun 30, 2020
TherapeuticsMD Q2 2020 Earnings Report
Reported financial results for the second quarter, showing resilience despite the COVID-19 pandemic.
Key Takeaways
TherapeuticsMD reported a net product revenue of $10.7 million for Q2 2020. The company focused on reducing operating expenses and reorienting the sales force. Net loss for the quarter was $52.0 million, or $0.19 per basic and diluted share.
Total net product revenue was $10.7 million despite COVID-19 impacts.
ANNOVERA prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period.
IMVEXXY new prescriptions increased 33% for the eight weeks ended July 24, 2020 over the previous eight week period.
Operating expenses decreased by $9.2 million to $51.3 million.
TherapeuticsMD
TherapeuticsMD
Forward Guidance
TherapeuticsMD is focused on driving revenue and achieving its goal of reaching EBITDA break even in 2021.